|Author(s)/Faculty: Nathan C. Steinle, MD; Caroline Baumal, MD; Lejla Vajzovic, MD, FASRS|
|Release Date: 3/16/2022||Expiration Date: 3/15/2023|
|Credit Type: CME / CME with ABO Continuing Certification ||Number of Credits: 0.75|
|Content Type: Lecture||Provider: |
|The advanced form of age-related macular degeneration (AMD), geographic atrophy (GA) leads to a progressive and irreversible loss of visual function. Genetic variants of several complement factor genes have been identified as risk factors for the development of AMD and GA, and dysregulation of the complement pathway has been implicated in the pathogenesis of AMD. Currently there are no approved therapies for the management of GA, but novel therapies that target components of the complement pathway are under clinical review. These novel, emerging targeted therapies have the potential to delay the progression of GA and ultimately improve GA outcomes. Within this CME activity, experts in the field will examine the role of the complement pathway in the pathogenesis of AMD and evaluate the clinical efficacy of emerging approaches that target the complement cascade for their potential to treat GA secondary to AMD.